350 rub
Journal Technologies of Living Systems №3 for 2013 г.
Article in number:
Molecular-genetics pathology of gastric cancer
Keywords: gastric cancer DNA methylation gene expression tumor molecular-genetics markers
Authors:
M.V. Nemtsova, I.I. Bykov, N.V. Checunova, D.V. Zaletaev, A.I. Glukhov, T.V. Kchorobrich
Abstract:
The paper presents an analysis of the literature and our own research on the original panel of molecular markers, including changes in tumor DNA, RNA and protein expression. We investigated aberrant methylation of CDH1, RASSF1A, MLH1, N33, DAPK, gene expression of hTERT, metalloproteinases MMP-7, MMP-9, survivin, COX-2, p53, and telomerase activity in 106 gastric tumor samples obtained intraoperatively, 53 gastric tumors samples obtained endoscopically, and 50 biopsy specimens obtained from patients with chronic calculous cholecystitis (comparison group). The values оf the parameters of original panel in the tumor were significantly different from the control group, so they can make the system of new molecular markers of gastric cancer. This system can be used in the diagnostics of gastric cancer, as well as for dynamic monitoring of the operated patients.
Pages: 36-47
References
  1. Statistika zlokachestvennykh novoobrazovanijj v Rossii i stranakh SNG v 2006 g. // Vestnik RONC im. N.N.Blokhina RAMN. 2008. T. 19. № 2. S. 53.
  2. Aruin L.I., Kapuller L.L., Isakov V.A. Morfologicheskaja diagnostika boleznejj zheludka i kishechnika. M.: Triada-KH. 1998. 496 s.
  3. Ageenko A.I. Novaja diagnostika raka: teorija, diagnostika, lechenie: Uch. metod. posobie dlja vrachejj. M.: Medicina XXI. 2004. 408 s.
  4. Nemcova M.V., Zemljakova V.V., ZHevlova A.I., Babenko O.V., Strelnikov V.V., Vasilev E.V.,Drozd O.V., Bochkov N.P., Zaletaev D.V. Profil metilirovanija genov-supressorov opukholevogo rosta pri razlichnykh formakh raka // Vestnik Instituta molekuljarnojj mediciny MMA
    im. M.I.Sechenova. M. 2002. № 2. S. 65 - 84.
  5. Mikhajjlov I.V., Beljakovskijj V.M., Al-JAkhri A.K., Prigozhaja T.I., Bondarenko V.M.Primenenie onkomarkerov SA-19-9 i REHA dlja ocenki verojatnosti peritonealnojj disseminacii u bolnykh rasprostranennym rakom zheludka // Vestnik khirurgicheskojj gastroehnterologii. 2010. № 1. S. 23 - 28.
  6. Zaletaev D.V., Strelnikov V.V., Nemcova M.V.Sistemy geneticheskikh i ehpigeneticheskikh markerov v DNK-diagnostike zlokachestvennykh obrazovanijakh / V kn.: «Sistemy geneticheskikh i ehpigeneticheskikh markerov v diagnostike onkologicheskikh zabolevanijj» (pod red. M.A. Pal­cevaiD.V.Zaletaeva).M. 2009. S. 7 - 76.
  7. Jang B.-G., Kim W.H.Molecular Pathology of Gastric Carcinoma // Pathobiology. 2011. V. 78. P. 302 - 310.
  8. Vauhkonen M., Vauhkonen H., Sipponen P. Pathology and molecular biology of gastric cancer // Best Pract. Res. Clin. Gastroenterol. 2006. V. 20. P. 651 - 674.
  9. Cavallaro U., Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer // Nature Rev. Cancer. 2004. V. 4. P. 118 - 132.
  10. Huntsman D.G., Carneiro F., Lewis F.R., Mac-Leod P.M., Hayashi A., Monaghan K.G., Maung R., Seruca R., Jackson C.E., Caldas C.Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations // N. Engl. J. Med. 2001. V. 344. P. 1904 - 1909.
  11. Humar B., Blair V., Charlton A., More H., Martin I., Guilford P. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man // Cancer Res. 2009. V. 69. P. 2050 - 2056.
  12. Humar B., Guilford P. Hereditary diffuse gastric cancer: a manifestation of lost cell polarity // Cancer Sci. 2009. V. 100. P. 1151 - 1157.
  13. Hollstein M., Sidransky D., Vogelstein B., Harris C. P53 mutations in human cancers // Science. 1991. V. 253. P. 49 - 53.
  14. Fenoglio-Preiser C., Wang J., Stemmermann G., Noffsinger A. TP53 and gastric carcinoma: a review // Hum. Mutat. 2003. V. 21. P. 258 - 270.
  15. Shiao Y., Rugge M., Correa P., Lehmann H., Scheer W. P53 alteration in gastric precancerous lesions // Am. J. Pathol. 1994. V. 144. P. 511 - 517.
  16. Subramaniam M. M., Chan J.Y., Yeoh K.G., Quek T., Ito K., Salto-Tellez M. Molecular pathology of RUNX3 in human carcinogenesis // Biochim. Biophys. Acta. 2009. V. 1796. P. 315 - 331.
  17. Li Q.L., Ito K., Sakakura C. et al. Causal relationship betweenthe loss of RUNX3 expression and gastric cancer // Cell. 2002. V. 109. P. 113 - 124.
  18. Yano T., Ito K., Fukamachi H., Chi X.Z., Wee H.J. et al.The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor induced apoptosis // Mol. Cell Biol. 2006. V. 26. P. 4474 ? 4488.
  19. Peng Z., Wei D., Wang L. et al. RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer // Clin. CancerRes. 2006. V. 12. P. 6386 - 6394.
  20. Glukhov A.I., Vysockaja O.V., Gordeev S.A. i dr.Telomeraza, servivin i ciklooksigenaza-2 kak misheni dlja diagnostiki opukholevykh zabolevanijj cheloveka. V kn. «Vvedenie v molekuljarnuju diagnostiku» (pod red. akad. M.A. Pal­ceva). M.: Medicina. 2010. S. 225 - 261.
  21. Nobili S., Bruno L., Landini I., Napoli C., Bechi P.Genomic and genetic alterations influence the progression of gastric cancer // World J. Gastroenterol. 2011. V. 17. № 3. P. 290 - 299.
  22. Bacani J., Zwingerman R., Di Nicola N. et al. Tumor microsatellite instability in early onset gastric cancer // J. Mol. Diagn. 2005. V. 7.  P. 465 - 477.
  23. Lee H.S., Choi S.I., Lee H.K. et al. Distinct clinical features and outcomes of gastric cancers with microsatellite instability // Mod. Pathol. 2002. V. 15. P. 632 ? 640.
  24. Yamamoto H., Imai K., Perucho M. Gastrointestinal cancer of the microsatellite mutator phenotype pathway // J. Gastroenterol. 2002. V. 37. P. 153 - 163.
  25. Issa J.P. CpG island methylator phenotype in  cancer // Nat. Rev. Cancer. 2004. V. 4. P. 988 - 993.
  26. Nemcova M.V., Babajan A.JU., Bykov I.I. i dr. Anomalnoe metilirovanie genov CDH1, RASSF1A, MLH1, N33, DAPK v opukholevom i morfologicheski neizmenennom (neopukholevom) ehpitelii zheludka // Rossijjskijj onkologicheskijj zhurnal. 2011. № 5. C. 21 - 25.
  27. Kim T., Jong H., Jung Y., Kang G., Bang Y. DNA hypermethylation in gastric cancer // Aliment. Pharmacol. Ther. 2004. V. 20. P. 131 - 142.
  28. Jee C.D., Kim M.A., Jung E.J., Kim J., Kim W.H.Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma // Eur. J. Cancer. 2009. V. 45. P. 1282 - 1293.
  29. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations // Science. 2002. № 295.
    R. 2387 - 2392.
  30. Will H., Hinzmann B.cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment // Eur. J. Biochem. 1995. V. 231.
    P. 602 - 608.
  31. CHernousov A.F., KHorobrykh T.V., Bykov I.I., Nemcova M.V. i dr. // Pervyjj opyt ispolzovanija markerov molekuljarno-geneticheskojj nestabilnosti slizistojj v diagnostike raka zheludka // Vestnik khirurgicheskojj gastroehnterologii. 2011. № 4. C. 4 - 13.